MediWound Files Annual Report on Form 20-F

Rhea-AI Summary

MediWound (Nasdaq: MDWD) filed its annual report on Form 20-F with the U.S. Securities and Exchange Commission on March 5, 2026 for the fiscal year ended December 31, 2025.

The filing, which includes audited financial statements, is available on the SEC website and the company's investor relations site. Shareholders may request a free hard copy by email or post.

Key Figures

Fiscal year end: December 31, 2025 Form type: Form 20-F Filing date: March 5, 2026

3 metrics

Fiscal year end December 31, 2025 Period covered by Form 20-F annual report

Form type Form 20-F Annual report filed with the SEC for 2025

Filing date March 5, 2026 Date annual report on Form 20-F was filed

Market Reality Check

Price: $17.45 Vol: Volume 87,154 is close to...

normal vol

$17.45 Last Close

Volume Volume 87,154 is close to the 20-day average of 84,422, indicating typical trading interest before this filing. normal

Technical Shares at $17.45 are trading below the 200-day MA of $18.54 and about 22.46% under the 52-week high.

Peers on Argus

MDWD was up 2.33% ahead of the filing, while notable peer moves were mixed: TNYA...

1 Down

MDWD was up 2.33% ahead of the filing, while notable peer moves were mixed: TNYA’s scanner reading showed a 5.18% decline, and other biotech peers had varied directions, pointing to stock-specific, not sector-driven, dynamics.

Historical Context

5 past events · Latest: Feb 19 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Earnings date notice	Neutral	+0.9%	Announced timing for Q4 and full-year 2025 results and call.
Feb 17	Conference appearances	Neutral	+2.6%	Planned presentations at two healthcare investor conferences.
Jan 12	Corporate outlook	Neutral	-7.9%	Corporate update and multi-year financial outlook ahead of JPM conference.
Dec 10	Clinical data update	Positive	+3.8%	Peer-reviewed data supporting NexoBrid effectiveness in traumatic tattoo prevention.
Nov 20	Quarterly earnings	Neutral	-5.6%	Q3 2025 financial results and corporate update, including funding and trials.

Pattern Detected

Recent MDWD news often led to noticeable but mixed price reactions, with financial updates sometimes followed by declines and clinical data seeing more positive responses.

Recent Company History

Over the last several months, MediWound has alternated between financial, corporate, and clinical updates. A November 2025 earnings report with Q3 revenue of $5.4M saw a -5.6% move, while a January 2026 corporate and outlook update coincided with a -7.86% reaction. In contrast, December 2025 clinical data for NexoBrid produced a 3.79% gain. Conference and event announcements in February 2026 generated modestly positive moves. Today’s Form 20-F filing adds formal, audited detail around the 2025 fiscal year already previewed in recent 6-Ks.

Market Pulse Summary

This announcement centers on MediWound’s formal filing of its 2025 Form 20-F, providing audited fina...

Analysis

This announcement centers on MediWound’s formal filing of its 2025 Form 20-F, providing audited financial statements and detailed risk disclosures. It complements recent 6-Ks that reported a $23.9M net loss, an accumulated deficit of $228.9M, and 12,835,148 shares outstanding. Investors reviewing the filing may focus on the company’s dependence on NexoBrid, its new GMP facility, and progress of the EscharEx Phase III VALUE trial as they assess long-term prospects and capital needs.

Key Terms

form 20-f

1 terms

form 20-f regulatory

"announced that it has filed its annual report on Form 20-F for the fiscal year"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

AI-generated analysis. Not financial advice.

MediWound Files Annual Report on Form 20-F

YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on March 5, 2026. The annual report can be accessed on the SEC’s website at http://www.sec.gov, as well as via the Company’s investor relations website at http://ir.mediwound.com.

The Company will provide a hard copy of its annual report on Form 20-F, including its audited financial statements, free of charge, to its shareholders upon request. Request should be directed in writing by email to jeremy@lifesciadvisors.com or by post to MediWound Ltd., 42 Hayarkon St., Yavne 8122745, Israel.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx^®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

MediWound Contacts:
Hani Luxenburg         Chief Financial Officer MediWound Ltd. ir@mediwound.com		Daniel Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com

FAQ

What did MediWound (MDWD) file on March 5, 2026?

MediWound filed its annual report on Form 20-F for the fiscal year ended December 31, 2025. According to the company, the filing includes its audited financial statements and is available on the SEC and investor relations websites for review.

How can shareholders obtain a hard copy of MediWound's 20-F (MDWD)?

Shareholders can request a free hard copy of the Form 20-F by written request to the provided contacts. According to the company, requests should be emailed to jeremy@lifesciadvisors.com or mailed to the provided Yavne, Israel address.

Where is MediWound's (MDWD) Form 20-F for 2025 available online?

The 20-F is available on the U.S. SEC website and on MediWound's investor relations site. According to the company, the SEC filing can be accessed at http://www.sec.gov and at http://ir.mediwound.com.

What fiscal period does MediWound's March 5, 2026 Form 20-F cover?

The Form 20-F covers MediWound's fiscal year ended December 31, 2025. According to the company, the filing includes the audited financial statements for that fiscal year and related disclosures.

Does MediWound's Form 20-F include audited financial statements?

Yes, the Form 20-F includes audited financial statements for the fiscal year ended December 31, 2025. According to the company, those audited statements are part of the annual report available to investors and shareholders.